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ORIGINAL ARTICLE
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Ajna Uzuni1
| Jaber El-Bashir2 | Dragos Galusca2 | Sirisha Yeddula3 |
Shunji Nagai3 | Atsushi Yoshida3 | Marwan S. Abouljoud3 | Zaher K. Otrock1
1

Department of Pathology, Wayne State
University School of Medicine, Transfusion
Medicine, Henry Ford Hospital, Detroit,
Michigan, USA
2
Department of Anesthesiology, Pain
Management and Perioperative Medicine,
Henry Ford Hospital, Detroit, Michigan, USA
3

Transplant and Hepatobiliary Surgery, Henry
Ford Hospital, Detroit, Michigan, USA

Abstract
Background and Objectives: Orthotopic liver transplantation (OLT) has been associated with high blood transfusion requirements. We evaluated the transfusion needs
and frequency of alloimmunization to RBC antigens among OLT recipients pre- and
post-transplantation.
Materials and Methods: We reviewed the medical records of patients who underwent a first OLT between January 2007 and June 2017. Transfusions given only dur-
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ing the perioperative period, defined by 1 week before OLT until 2 weeks following
OLT, were included in this study. Records were reviewed in June 2019 for updated
antibody testing results.
Results: A total of 970 patients underwent OLT during the study period. The median
age of patients was 57 years; 608(62.7%) were male. During the perioperative
period, transfused patients received an average of 10.7 (10.7) RBC units, 15.6
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(16.2) thawed plasma units and 4.1 (4.3) platelet units. At the time of OLT, a total
of 101 clinically significant RBC alloantibodies were documented in 58(5.98%)
patients. Fifty-three of these antibodies were directed against Rh blood group
antigens. Twenty-two (37.9%) patients had more than one alloantibody. Patients
with alloimmunization before OLT (N = 58) received perioperatively comparable
number of RBCs to non-alloimmunized patients (10.5  10.6 vs. 9.6  10.7;
p = 0.52). There was no significant difference in perioperative or intraoperative RBC
transfusion between patients with one alloantibody and those with multiple alloantibodies. Only 16 patients (16/737; 2.17%) developed new alloantibodies at a median
of 61 days after OLT. The overall alloimmunization rate was 9.8% (72/737), and
female patients were more likely to be alloimmunized.
Conclusion: Blood transfusion requirements in OLT remain high. However, the rate
of RBC alloimmunization was not higher than the general patient population.
KEYWORDS

alloimmunization, orthotopic liver transplantation, RBC, transfusion
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I N T R O D U CT I O N

The following variables were collected for each patient: gender;
age; race; diagnosis; recipient ABO blood group and Rh type; antibody

Orthotopic liver transplantation (OLT) has advanced throughout the

screening (indirect antiglobulin test [IAT]) and antibody specificity;

years and has become the standard of care for end-stage liver disease [1].

transfusion requirements (number of units of RBCs, thawed plasma,

It has significantly improved the outcome and survival rate of patients with

platelets and cryoprecipitate) during the perioperative period and

acute liver failure [2]. With the improvement of surgical techniques,

alloimmunization at any time after OLT with antibody specificity. Records

implementing preoperative optimization, use of antifibrinolytic medications

were reviewed in June 2019 for updated antibody testing results.

and better transfusion management, OLT has witnessed a significant

Antibody screening (IAT) was performed using solid-phase tech-

decrease in transfusion requirements [3, 4]. In addition, accumulating

nology on a fully automated analyser Galileo Neo (GALILEO: Immucor

evidence in the medical literature indicates that high transfusion require-

Inc., Norcross, GA) using a two-cell screen. Positive samples were

ments on any blood component are associated with adverse events,

investigated for antibody identification with a 14-cell panel. Advanced

prolonged hospital stays and poor postoperative outcomes [5–9].

immunohaematologic investigations would include manual methods,

However, OLT is still associated with major blood loss and consequently

such as adsorption and elution, whenever required. All tests were per-

high blood transfusion requirements [10], which can extend postoperatively

formed according to manufacturers’ instructions.

due to bleeding complications and abnormal haemostasis [11].

During the study period, the blood bank utilized leukoreduced

Immunohaematologic complications can result from a blood transfu-

blood products, pooled platelet concentrates (available until 2015) or

sion and can complicate patient management [12]. Due to multiple blood

apheresis platelets, fresh frozen plasma (FFP) or plasma frozen within

transfusions, liver transplant patients can get alloimmunized to red blood

24 h (PF24) and cryoprecipitate (each unit was a pool of five units).

cell (RBC) antigens. RBC alloimmunization can cause adverse events

For OLT, the blood bank would start issuing irradiated RBCs and

resulting in acute or delayed haemolytic transfusion reactions and can

platelets on the day of the transplant.

result in difficulty locating compatible blood [13]. With the institution of
patient blood management in most institutions and with the evidence
supporting restrictive haemoglobin thresholds, there has been a decline

Immunosuppressive regimen

in transfused RBC units [14]. However, blood transfusion remains the
most common procedure performed during a patient’s hospitalization

Per our protocol, induction immunosuppression included rabbit anti-

with more than 11 million RBC units transfused annually in the United

thymocyte globulin at a dose of 0.5–1.0 mg/kg on postoperative days 1, 3

States [15]. Studies have reported an alloimmunization incidence of

and 5 or basiliximab at 20 mg on postoperative days 0 and 4. The mainte-

6%–23% in OLT [16, 17], which is higher than the 1%–5% of the general

nance immunosuppression regimen consisted of tacrolimus, mycophenolate

patient population [18–20].

mofetil and steroids. Tacrolimus was started within 5 days after transplanta-

With a very active liver transplant programme at our institution,

tion. The target trough levels of tacrolimus were 8–12 ng/ml during the first

we aimed, through the current study, to determine the transfusion

3 months, 6–10 ng/ml between months 3 and 12 and 5–8 ng/ml after

needs in OLT during an 11-year period. In addition, we wanted to

12 months. Mycophenolate mofetil was administered 500 mg every 12 h

evaluate the frequency of alloimmunization and its specificity to RBC

and was withdrawn by 1 year. Steroids were tapered off by 3 months.

antigens among liver transplantation recipients.

Anaesthetic and surgical procedures
MATERIALS AND METHODS
Prior to liver transplant surgery, patients were always evaluated by
This study was performed at Henry Ford Hospital, an 877-bed tertiary

the anaesthesia and surgery teams. All patients received general

academic medical centre located in Detroit, Michigan. The study was

anaesthesia with endotracheal intubation, standard American Society

approved by our institutional review board and was carried out in

of Anaesthesiologists intraoperative monitoring, central venous and

accordance with the Helsinki declaration. Informed consent was

invasive arterial blood pressure monitoring, pulmonary artery pressure

waived due to the study design. Patients were identified through the

monitoring and transesophageal echocardiography assessment of

Liver Transplant database. Electronic medical records and blood bank

cardiac function. For patients who required intraoperative continuous

files of 970 consecutive patients who underwent a first OLT over an

veno-venous haemofiltration, dialysis access was obtained. Optimally

11-year period (January 2007 through June 2017) were reviewed.

balanced anaesthesia with inhaled agents, opioids and muscle relax-

Patients undergoing combined liver and other organ transplants

ants was provided by the liver transplant anaesthesiologist. Donor’s

were included in the analysis. Patients who had a second OLT

livers were flushed with histidine-tryptophan-ketoglutarate solution.

were excluded. Transfusions given only during the perioperative

Surgical techniques were used as described previously [21]. Blood

period were included in this database. The perioperative period was

product transfusion was managed based on the clinical judgement of

defined as the period spanning 1 week before OLT until 2 weeks

the anaesthesiologist utilizing intraoperative monitoring parameters,

following OLT.

cell salvage, antifibrinolytics and coagulation testing results.
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Transfusion management

by haemodynamic instability, intraoperative course, blood loss, oozing
from the surgical field or other surgical complications, which may

The liver transplant coordinator notified the blood bank of a potential

extend the duration of the procedure. In addition, laboratory values,

liver transplant as soon as a donor was identified. The blood bank

mostly haemoglobin, platelet count international normalized ratio (INR)

records of recipients were reviewed for previous alloimmunization to

and fibrinogen level, were used to support the transfusion needs.

RBC antigens. A recipient sample was sent for antibody screening

Thromboelastography was not available during the study period.

(IAT). If the previous and current antibody screening were negative,
20 ABO-compatible RBC units were reserved for the recipient. If
clinically significant alloantibodies to RBC antigens were identified by

Statistical analysis

history or on the current antibody screening, 30 antigen-negative
serologically cross-matched RBC units were reserved. The blood bank

Descriptive statistics were presented for variables. Results were

would keep an additional 10–15 antigen-negative uncross-matched

expressed as mean  SD or median plus range for continuous vari-

RBC units for patients with more than one alloantibody; during

ables, and as numbers with percentages for categorical variables. The

massive bleeding, we would use the uncross-matched units and

Mann–Whitney U-test for continuous variables was used to compare

reserve the compatible units for the end of surgery. Blood would be

the groups when applicable. Pearson’s Chi-square test or Fisher’s

stocked in the blood bank 24 h in advance of the day of the trans-

exact test was used to compare categorical variables. Results were

plant. Thawed plasma units were kept in the blood bank inventory

considered significant at p < 0.05 using two-sided tests. SPSS version

at all times (6–10 Group A units, 4 Group B, 2 Group O and 2 Group

17.0 software was used for the statistical analysis of data.

AB units). Additional plasma units would be thawed as needed.
Platelet units were provided as needed, and cryoprecipitate units
were thawed upon request. Blood products were ordered by the

RE SU LT S

anaesthesiologist.
The criteria for transfusion were the available AABB criteria at the

A total of 970 patients underwent OLT from January 2007 to June

time for the pre- and post-operative transfusion. During transplant sur-

2017. The median age of patients was 57 years (range: 16.6–74.6 years);

gery, transfusion was dictated by the intraoperative needs as reflected

608 (62.7%) were male. Most of the patients were Caucasian (N = 815;

TABLE 1

Blood component usage in patients undergoing orthotopic liver transplantation (N = 970)
Number of transfused
patients (%)

Mean (units)

SD

RBC

874 (90.1)

10.7

10.7

FFP/PF24

877 (90.4)

15.6

16.2

Platelets

559 (57.6)

4.1

4.3

Cryoa

584 (60.2)

3.6

3.6

pRBC

134 (13.8)

3.6

5.1

FFP/PF24

Blood component

Median (units)

Minimum

Maximum

7

1

101

11

1

128

3

1

32

2

1

32

2

1

55

Perioperative

Preoperative

151 (15.6)

8.7

8.8

6

1

54

Platelets

71 (7.3)

2.0

1.8

1

1

11

Cryoa

40 (4.1)

2.8

3.3

2

1

17

Intraoperative
pRBC

782 (80.6)

5.9

6.5

4

1

57

FFP/PF24

831 (85.7)

10.2

8.9

8

1

82

Platelets

422 (43.5)

2.0

1.4

2

1

10

Cryoa

490 (50.5)

2.7

2.2

2

1

17

729 (75.2)

5.8

6.6

4

1

88

Postoperative
pRBC
FFP/PF24

508 (52.4)

7.6

12.4

4

1

117

Platelets

385 (39.7)

3.4

4.0

2

1

31

249 (25.7)

2.5

3.2

2

1

31

Cryo

a

Abbreviations: Cryo, cryoprecipitate; FFP, fresh frozen plasma; PF24, plasma frozen within 24 h; RBC, red blood cells; SD, standard deviation.
a
Each cryo unit represents a pool of five units.
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TABLE 2

Alloantibodies to RBC antigens identified serologically or by history prior to orthotopic liver transplantation

Antibody specificity

Number of patients
(total N = 58)

Blood group
system/antibody

E

11

Rh

Jka

6

Anti-E

No. of patients
with alloantibodies
(total N = 101)

26

D

5

Anti-D

13

M

4

Anti-C

10

C

3

Anti-c

4

c

1

E, K

4

K

3

Lea

Kell
Anti-K

16

Kidd

2

Anti-Jka

11

E, Jk

2

Anti-Jkb

3

C, E, K

1

E, c, K

1

a

S

1

E, c

1
a

1

E, Fya, Jkb

1

E, K, Jkb

1

D, C, S

1

D, C, Lea

1

E, Fy

D, Fy

a

Duffy
Anti-Fya

5

MNS
Anti-M

4

Anti-S

4

Lewis
Anti-Lea

4

Colton
Anti-Cob

1

1

D, K

1

C, D, E, K, Fya, Jka, Lea
C, D, K, Jk

a

1
1

C, D, K

1

C, D, K, S, Co

b

E, c, Fya, Jkb
a

E, K, S, Jk

1
1
1

84%). Sixty-eight patients had a simultaneous liver-kidney transplant and

had more than one alloantibody. Of these, 10 had two antibodies,

eight patients had multivisceral transplant.

7 had three, 3 had four, 1 had five and 1 had seven antibodies

During the perioperative period, transfused patients received

(Table 2). One patient had warm autoantibodies, and another had

an average of 10.7 (10.7) RBC units, 15.6 (16.2) thawed plasma

cold autoantibodies on antibody screens at the time of liver trans-

units, 4.1 (4.3) platelet units and 3.6 (3.6) cryoprecipitate units.

plantation. In addition, six patients had a positive antibody screen

Table 1 summarizes the perioperative blood component usage

with non-specific findings.

in OLT.
At the time of OLT, a total of 101 clinically significant RBC allo-

Patients with history of RBC alloimmunization before OLT (N = 58)
received perioperatively comparable number of RBCs to non-alloimmunized

antibodies were documented in 58 (5.98%) patients through posi-

patients (10.5  10.6 vs. 9.6  10.7; p = 0.518); 54 (93.1%) of the

tive antibody screening and/or history of alloimmunization to RBC

alloimmunized patients received perioperative RBC transfusions. There was

antigens. The patients included 21 males and 37 females, with a

no significant difference in perioperative or intraoperative RBC transfusion

median age of 56 years (range: 20–70 years). Forty-nine (84.5%) of

between patients with one alloantibody and those with multiple alloanti-

these patients were Caucasian. These antibodies were formed

bodies (9.6  7.9 units vs. 12.2  13.8 units perioperatively; p = 0.36 and

against a range of antigens as listed in Table 2. Fifty-three (53%) of

4.6  5.3 units vs. 5.6  7.8 units intraoperative; p = 0.67, respectively).

these antibodies were directed against the Rh blood group

Serological follow-up with antibody screen was available for

antigens; the next common antibodies were against the Kell

737 (76%) patients with a median follow-up of 23 (interquartile range

(16 antibodies), Kidd (14 antibodies), MNS (8 antibodies) and Duffy

[IQR], 14–260) days following OLT; 696/737 (94.4%) patients received peri-

(5 antibodies) blood group antigens. Twenty-two (37.9%) patients

operative RBC transfusion. The average number of antibody screening
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TABLE 3

Characteristics and immunohaematologic findings of patients who had alloimmunization after liver transplantation

Age (yrs)

Gender

Race

No. of transfused
RBC units periop

Interval (OLT - last ab
screen before Allo)

Post-OLT new
ab specificity

DAT
at Allo

Interval
(OLT – Allo)

1

56.3

F

C

27

15.3 months

Anti-E

NP

15.6 months

2

53.6

M

A

10

NP

Anti-E

Negative

3.5 months

3

59.9

M

C

10

13 days

Anti-E

Negative

81 days

4

58.9

M

A

17

NP

Anti-E

NP

8 days

5

43.0

M

C

12

6

37.4

F

C

8

7†

55.0

F

C

19

58 days

Anti-c

NP

67 days

8

57.8

M

C

6

10 days

Anti-K

NP

28 days

Pts

4 days

Anti-D*

Positive (IgG)

14 days

NP

Anti-D*

Positive (IgG)

3 days

9

62.5

F

C

5

NP

Anti-K

NP

21.5 months

10

69.0

F

C

20

NP

Anti-K

NP

3.7 months

11

59.9

M

A

6

NP

Anti-K

NP

55 days

12

52.6

F

C

11

4.7 months

Anti-Kpa

NP

7.3 months

Positive (IgG)

15 days

Positive (IgG)

22 days

a

13

38.7

F

C

5

NP

Anti-Kp

14

62.0

F

C

7

NP

Anti-Jkb
b

15

41.4

F

A

6

7.2 months

Anti-Jk

16†

22.2

F

A

6

NP

Anti-C, Fya, K

NP

20.4 months

Positive (IgG, C3)

15 days

Abbreviations: A, African American; Ab, antibody; Allo, alloimmunization; C, Caucasian; DAT, direct antiglobulin test; F, female; M, male;
NP, not performed; OLT, orthotopic liver transplantation; Pts, patients; yrs, years.
*Passenger lymphocyte syndrome.
†
Patients 7 and 16 had anti-E + Jka and anti-E, respectively, before OLT.

post-OLT was 1.49. Only 16 patients (16/737; 2.17%) developed new allo-

Twenty-four D-negative patients were transfused with D-positive

antibodies after OLT: anti-E (four patients), anti-K (four patients), anti-K and

RBC units (median 8.5 units; range: 1–90 units) perioperatively. None

anti-C and anti- Fya (1), anti-Jkb (2), anti-Kpa (2), anti-D (2) and anti-c (1).

of the patients with available serological follow-up (N = 19) devel-

These patients included 6 males and 10 females, with a median age of

oped a positive antibody screen after a median serological follow-up

55.6 years (range: 22.2–69 years). Identification of alloantibodies was at a

of 41.9 months (range: 17 days–127.7 months).

median of 61 (IQR, 15–191.5) days after OLT. Table 3 summarizes the characteristics and immunohaematologic findings of these patients. The overall
RBC alloimmunization rate in our cohort was 9.8% (72/737). Female

DI SCU SSION

patients were more likely to be alloimmunized compared to males (45/362
[12.4%] females and 27/608 [4.4%] males; p < 0.001). We had a signifi-

We reviewed the medical records of OLT patients to determine their

cantly higher number of African American patients transfused peri-

perioperative transfusion requirements and the overall rate of

operatively compared to Caucasian patients (149/155, 96.1% vs. 725/

alloimmunization to RBC antigens. During the perioperative period,

815, 89%; p = 0.006). However, there was no significant difference in

transfused patients received an average of 10.7 (10.7) RBC units,

overall alloimmunization between African American patients and Cauca-

15.6 (16.2) thawed plasma units, 4.1 (4.3) platelet units and 3.6

sian patients (13/155, 8.4% vs. 59/815, 7.2%; p = 0.62).

(3.6) cryoprecipitate units. A total of 101 clinically significant RBC

Two D-positive patients receiving OLT from D-negative donors

alloantibodies were documented in 58(5.98%) patients at the time of

developed anti-D antibodies with positive direct antiglobulin test

OLT. Only 16 patients (16/737; 2.17%) developed new alloantibodies

(DAT) due to passenger lymphocyte syndrome. The first patient was a

after OLT. The overall alloimmunization rate was 9.8% (72/737), and

37-year-old female with primary sclerosing cholangitis who developed

female patients were more likely to be alloimmunized.

anti-D antibodies 3 days following OLT. She did not have evidence of

More than 90% of our OLT patients required RBC and plasma

haemolysis, was managed with immunosuppressive therapy and her

transfusions perioperatively, with an average of 10.7 and 15.6 units,

DAT was negative 43 days after OLT. The second patient was a

respectively. Most of the blood products were transfused intra-

43-year-old male with liver cirrhosis secondary to hepatitis C who devel-

operatively – RBCs and FFPs were transfused in almost 81% and 86%

oped anti-D antibodies 14 days following OLT. He did not show evi-

of patients, respectively. Our experience with the transfusion require-

dence of increased haemolysis. We did not have a close follow-up on

ments of blood products, especially intraoperative transfusions, is

his DAT.

consistent with the published literature on OLT [22, 23]. Still, higher
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transfusion requirements have been reported by others [7]. Although

The majority of our patients (68%) were alloimmunized to the Rh

the AABB transfusion guidelines are widely used [24, 25], transfusion

and Kell blood group antigens at the time of liver transplantation. The

practices remain variable among transplant centres.

question remains whether phenotypically matched blood for Rh and

The results of our study showed that more plasma has been

Kell would have a potential benefit in preventing alloimmunization in

transfused than RBCs, which is consistent with some studies [7, 26].

liver transplant candidates. A definitive answer to this question cannot

In fact, there is emerging literature that a higher plasma to packed

be provided based on our study. However, we can argue based on our

RBC transfusion ratio during liver transplantation is associated with a

findings that phenotypically matched RBCs might not be of great ben-

decreased need for RBC transfusions. In a retrospective study by

efit in this patient population. First, the rate of alloimmunization in

Pagano and colleagues, 188 patients were evaluated for the volume

our cohort at the time of liver transplantation (5.98%) was not

ratio of transfused plasma (PL Vol) to RBC (RBC Vol). A low PL

greater than the general patient population, and the rate of new

Vol/RBC Vol was associated with excess RBC transfusion with signifi-

alloimmunization post-liver transplant was even lower at 2.17%.

cant findings using logistic regression [26].

This makes it not worth the efforts needed to find phenotypically

Several studies reported on RBC alloimmunization before and,

matched RBCs during the pre-transplant period. Second, although

some of them, after OLT [12, 16, 17, 27–29]. Alloimmunization fre-

our study did not specifically assess the challenges in finding com-

quency ranged from 4% to 23% pre-OLT and from 1% to 7.5% post-

patible blood for alloimmunized patients, we generally did not face

OLT. Patients having multiple antibodies accounted for up to 45% of

difficulties in securing blood during the perioperative period. Based

alloimmunized patients. The results of the current study are compara-

on these observations, we believe providing phenotypically mat-

ble to previous findings: we documented pre-OLT and post-OLT

ched RBCs for Rh and Kell blood group antigens might be demand-

alloimmunization in 6% and 2% of patients, respectively; 38% of

ing and not of great benefit in liver transplant candidates. The risks

alloimmunized patients had multiple antibodies. The profile of anti-

of alloimmunization to RBC antigens need to be evaluated in large

body specificity, most commonly against the Rh and Kell blood group

prospective studies.

systems, is consistent with the reported literature [16, 17]. We identified

This study has several strengths including the large number of

two patients with passenger lymphocyte syndrome due to anti-D anti-

patients undergoing OLT over a long period of institution experience.

bodies. We cannot tell with certainty if these were the only two cases in

One of the limitations of this study is its nature and being dependent

our cohort as most passenger lymphocyte syndrome cases are subclini-

on medical record documentation. The possibility of data recording

cal, and even now, there is no standardized consensus on screening for

bias cannot be excluded. Some parameters that would affect

passenger lymphocyte syndrome in transplant patients [30].

alloimmunization were not collected and these include pregnancy his-

In the current study, patients with RBC alloimmunization before

tory of female patients, transfusion history before 7 days prior to OLT

OLT received a comparable number of RBCs perioperatively to non-

and transfusion requirements after 14 days after OLT. Another limita-

alloimmunized patients. Our findings did not concur with others’ find-

tion relates to the lack of systematical time course for antibody

ings [28, 29]. Solves and colleagues [28] reviewed 654 OLT patients

screening as reflected in the relatively short median antibody screen

from Spain, 27 of whom were alloimmunized before OLT. The investi-

follow-up time of 23 days; thus, new alloantibodies might have been

gators found that patients who suffered “any immunohaematologic

missed. The lack of a protocol for detecting delayed serologic/

incident” including those who were alloimmunized received more

haemolytic transfusion reactions is another limitation.

RBCs during hospital admission. The authors did not give a discussion

In conclusion, despite blood management, blood transfusion

about their results. In another study [29], only 192 Chinese recipients

requirements in OLT remain high during the perioperative period.

of liver transplants were surveyed with 17 (8.8%) patients having RBC

However, the rate of alloimmunization to RBC antigens was not

alloantibodies. The authors found that the presence of RBC alloanti-

higher than the general patient population. More importantly, RBC

bodies was associated with increased blood requirements; however,

alloimmunization in this patient population did not increase RBC utili-

they acknowledged that the numbers of cases and events were small

zation. Implementing a patient blood management programme is

and that their perioperative variables were highly heterogeneous, and

needed to address preoperative anaemia optimization, minimizing

thus cautioned the readers that conclusions were to be verified. The

blood loss, implementation of restrictive transfusion thresholds and

findings of these two studies did not seem to be based on biologic basis,

other principles to minimize blood transfusion and improve outcome.

and definitive conclusions in regard to alloimmunization and increased

There is also a need to evaluate the appropriateness of blood transfu-

blood requirements need to be investigated in large prospective studies.

sions in OLT, a process that might not be easy to apply especially in

We did not find a statistically significant difference in RBC trans-

the intraoperative setting.

fusion requirements in patients with single versus multiple antibodies.
Contrary to our findings, Shariatmadar and colleagues noted that
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